Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small.

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006 Mark.

Treatment of Stage IV Non-small Cell Lung Cancer

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients Jean-Louis Pujol, MD, Patrick.

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Aminah Jatoi, MD, Dawn Aranguren, PA-C Journal of Thoracic Oncology

Volume 155, Issue 1, Pages (January 2019)

Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative.

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Ethnic Differences in the Management of Lung Cancer in New Zealand

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

IASLC 6th Latin American Conference on Lung Cancer

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Journal of Thoracic Oncology

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Induction Therapy For Locally Advanced Thymoma

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

A Review of First-Line Treatment for Small-cell Lung Cancer

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Mark A. Socinski, MD Journal of Thoracic Oncology

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer Mark R. Green, MD, Howard West, MD, Mark A. Socinski, MD, Joanne Willey, RN, OCN, Laura Daniels, BA, Kristine Lemke, MBA, George Rafferty, BA, Lou Iovino, MA Journal of Thoracic Oncology Volume 4, Issue 8, Pages 983-987 (August 2009) DOI: 10.1097/JTO.0b013e3181adeefb Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Schema for Hoosier Oncology Group (HOG) trial evaluating the role of docetaxel consolidation in patients with a new diagnosis of stage III non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Case scenario for assessing prescribing plans of American medical oncologists. No changes were made in the case scenario during the entire period reported. Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Prescribing plans offered as selection options for the research study participants. The option “other” is routinely included to avoid driving research participants to a “forced choice” selection. Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Prescribing plans for a patient with a new diagnosis of stage IIIB non-small cell lung cancer (NSCLC) assessed in 987 American medical oncologists who participated in Network for Medical Communications and Research (NMCR) live research events between March 2005 and May 2007. Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Prescribing plans for a patient with a new diagnosis of stage IIIB non-small cell lung cancer (NSCLC) assessed in 427 American medical oncologists who participated in Network for Medical Communications and Research (NMCR) live research events between March and September 2007. Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Prescribing plans for a patient with a new diagnosis of stage IIIB non-small cell lung cancer (NSCLC) assessed in 427 American medical oncologists who participated in Network for Medical Communications and Research (NMCR) live research events between March and September 2007. Prescribing plans shown for two time frames, before and after American Society of Clinical Oncology (ASCO) 2007. Choices of “radiation followed by chemotherapy,” “chemotherapy alone,” and “other,” totaling 3% are not shown here. Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Prescribing plans for a patient with a new diagnosis of stage IIIB non-small cell lung cancer (NSCLC) assessed in 427 American medical oncologists who participated in Network for Medical Communications and Research (NMCR) live research events between March and September 2007. Prescribing plan data are shown for each specific research event with the inflection point coinciding with the Hoosier Oncology Group (HOG) data presentation at American Society of Clinical Oncology (ASCO) 2007. Journal of Thoracic Oncology 2009 4, 983-987DOI: (10.1097/JTO.0b013e3181adeefb) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions